CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Breast Cancer
Interventions: DRUG: CFI-402257|DRUG: Fulvestrant
Sponsor: Treadwell Therapeutics, Inc